The S&P 500 is currently less than 2% below its all-time high, and while no immediate alarm signals are present, a 15% correction could be next. Unlike bear-market bottoms that end dramatically with panic selling, bull-market tops tend to occur gradually and without major disruptions. Investors should be cautious not to expect a sudden crash at the market peak, as the final top often happens quietly over time.
The S&P 500's current market context shows a mixed breadth among 150 US stocks tradable on Pluang, with 87 rising and 62 falling as of Oct 21, 2026 03:02 WIB. Notable price changes include BlackBerry Limited up 8.46% at USD 8.85 with a typical hold time of 51 days and Pluang order activity heavily skewed to selling at 99%, Xpeng Inc - ADR up 7.60% at USD 9.91 with a hold time of 81 days and 90% sell orders, and General Motors Company down 6.89% at USD 77.05 with a hold time of 83 days and 95% sell orders. This snapshot provides a view of market dynamics as the S&P 500 approaches its all-time high.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
